000148157 001__ 148157
000148157 005__ 20250115151520.0
000148157 0247_ $$2doi$$a10.1016/j.ijpharm.2015.07.062
000148157 0248_ $$2sideral$$a91235
000148157 037__ $$aART-2015-91235
000148157 041__ $$aeng
000148157 100__ $$aCiriza, J.
000148157 245__ $$aGraphene oxide increases the viability of C2C12 myoblasts microencapsulated in alginate
000148157 260__ $$c2015
000148157 5060_ $$aAccess copy available to the general public$$fUnrestricted
000148157 5203_ $$aCell microencapsulation represents a great promise for long-term drug delivery, but still several challenges need to be overcome before its translation into the clinic, such as the long term cell survival inside the capsules. On this regard, graphene oxide has shown to promote proliferation of different cell types either in two or three dimensions. Therefore, we planned to combine graphene oxide with the cell microencapsulation technology. We first studied the effect of this material on the stability of the capsules and next we analyzed the biocompatibility of this chemical compound with erythropoietin secreting C2C12 myoblasts within the microcapsule matrix. We produced 160 μm-diameter alginate microcapsules with increasing concentrations of graphene oxide and did not find modifications on the physicochemical parameters of traditional alginate microcapsules. Moreover, we observed that the viability of encapsulated cells within alginate microcapsules containing specific graphene oxide concentrations was enhanced. These results provide a relevant step for the future clinical application of graphene oxide on cell microencapsulation.
000148157 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/DPI2011-28262-C04-01
000148157 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000148157 590__ $$a3.994$$b2015
000148157 591__ $$aPHARMACOLOGY & PHARMACY$$b43 / 255 = 0.169$$c2015$$dQ1$$eT1
000148157 592__ $$a1.298$$b2015
000148157 593__ $$aPharmaceutical Science$$c2015$$dQ1
000148157 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000148157 700__ $$aSaenz Del Burgo, L.
000148157 700__ $$0(orcid)0000-0003-3660-8651$$aVirumbrales-Muñoz, M.$$uUniversidad de Zaragoza
000148157 700__ $$0(orcid)0000-0003-2410-5678$$aOchoa, I.$$uUniversidad de Zaragoza
000148157 700__ $$0(orcid)0000-0001-5376-4440$$aFernandez, L. J.$$uUniversidad de Zaragoza
000148157 700__ $$aOrive, G.
000148157 700__ $$aHernandez, M. R.
000148157 700__ $$aPedraz, J. L.
000148157 7102_ $$11003$$2443$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Histología
000148157 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000148157 7102_ $$15004$$2605$$aUniversidad de Zaragoza$$bDpto. Ingeniería Mecánica$$cÁrea Mec.Med.Cont. y Teor.Est.
000148157 773__ $$g493, 1-2 (2015), 260-270$$pInt. j. pharm.$$tInternational Journal of Pharmaceutics$$x0378-5173
000148157 8564_ $$s624082$$uhttps://zaguan.unizar.es/record/148157/files/texto_completo.pdf$$yPostprint
000148157 8564_ $$s1013805$$uhttps://zaguan.unizar.es/record/148157/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000148157 909CO $$ooai:zaguan.unizar.es:148157$$particulos$$pdriver
000148157 951__ $$a2025-01-15-15:14:31
000148157 980__ $$aARTICLE